CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$999,994. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-15 | Ciechanover Isaac E. Chief Executive Officer | Option exercise · Restricted Stock Units | −5,908 | 3,938 | ||
| 2017-11-15 | Clark Mitchall G. EVP & Chief R & QA Officer | Option exercise | +7,212 | 166,342 | ||
| 2017-11-15 | Clark Mitchall G. EVP & Chief R & QA Officer | Option exercise · Restricted Stock Unites | −7,212 | 12,019 | ||
| 2017-11-15 | Fust Matthew K Director | Option exercise | +1,602 | 30,503 | ||
| 2017-11-15 | Fust Matthew K Director | Option exercise · Restricted Stock Units | −1,602 | 2,137 | ||
| 2017-11-15 | MCGRATH JOHN EVP & Chief Financial Officer | Option exercise | +7,697 | 128,654 | ||
| 2017-11-15 | MCGRATH JOHN EVP & Chief Financial Officer | Option exercise · Restricted Stock Units | −7,697 | 5,132 | ||
| 2017-11-15 | Gallagher Carol Giltner Director | Option exercise | +1,549 | 110,105 | ||
| 2017-11-15 | Gallagher Carol Giltner Director | Option exercise | +817 | 110,922 | ||
| 2017-11-15 | Gallagher Carol Giltner Director | Option exercise · Restricted Stock Units | −1,549 | 1,548 | ||
| 2017-11-15 | Gallagher Carol Giltner Director | Option exercise · Restricted Stock Units | −817 | 1,362 | ||
| 2017-11-14 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $13.41 | $30K | 419,778 |
| 2017-11-13 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $13.53 | $30K | 421,978 |
| 2017-10-27 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $13.60 | $30K | 424,178 |
| 2017-10-26 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $13.57 | $30K | 426,378 |
| 2017-10-16 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −6,000 | $14.35 | $86K | 343,305 |
| 2017-10-12 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $14.78 | $33K | 428,578 |
| 2017-10-11 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $15.25 | $34K | 430,778 |
| 2017-09-20 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $15.56 | $34K | 432,978 |
| 2017-09-19 | Ciechanover Isaac E. Chief Executive Officer | Sale | −2,200 | $15.51 | $34K | 435,178 |
Page 40 of 44 · 867 trades